To subscribe to our podcast and YouTube channel visit: https://www.youtube.com/@davisphinneyfdn/podcasts

More people with Parkinson's are impacted by the LRRK2 (often pronounced "Lark two") gene than you might expect.

The NEULARK study is a phase II clinical trial designed to investigate whether a new treatment being researched, NEU-411, can slow disease progression and improve quality of life for people with Parkinson’s disease. NEU-411 is an oral medication designed to inhibit overactivity of the LRRK2 gene.

In this episode of The Parkinson’s Podcast, we talk with Dr. Fatta Nahab about the NEULARK study. This episode is sponsored by Neuron23, who is also sponsoring the NEULARK study. Our guest, Dr. Nahab, is Vice President of Clinical and Digital Development for Neuron23. 

For more information about the NEULARK trial please visit:  https://parkinsonsresearchlrrk2.com/  or  https://clinicaltrials.gov/study/NCT06680830  

Season: 6 Episode: 19